Leptosins isolated from marine fungus Leptoshaeria species inhibit DNA topoisomerases I and/or II and induce apoptosis by inactivation of Akt/protein kinase B

Cancer Science

Volumn 96, Issue 11, 2005, Pages 816-824

  Yanagihara, Miyako ^a   Sasaki Takahashi, Noriko ^a   Sugahara, Tetsuo ^a   Yamamoto, Seiko ^a   Shinomi, Masahito ^a   Yamashita, Izumi ^a   Hayashida, Masashi ^a   Yamanoha, Banri ^a   Numata, Atsushi ^b   Yamori, Takao ^c   Andoh, Toshiwo ^a  

^a SOKA UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CASPASE 3; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; FUNGAL ENZYME; INDOLE DERIVATIVE; LEPTOSIN C; LEPTOSIN F; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CHROMOSOME ANALYSIS; CYTOTOXICITY; DNA DEGRADATION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; FUNGUS; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LEPTOSPHAERIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN TARGETING; STRUCTURE ANALYSIS;

APOPTOSIS; CELL LINE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; FUNGI; HUMANS; INDOLE ALKALOIDS; KIDNEY; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 29644440491     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00117.x     Document Type: Article

References (47)

1. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994; 303: 681-95.
2. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65: 635-92.
3. Wang JC. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q Rev Biophys 1998; 31: 107-44.
4. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzymes. Biochem Biophys Acta 1998; 1400: 83-105.
5. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191-218.
6. Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase H on DNA by m-AMSA. Proc Natl Acad Sci USA 1984; 81: 1361-5.
7. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochem Biophys Acta 1998; 1400: 155-71.
8. Utsugi T, Aoyagi K, Asao T et al. Antitumour activity of a novel quinolone derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 1997; 88: 992-1002.
9. Ishida RT, Mild T, Narita R et al. Inhibition of intracellular topoisomerase II by antitumor bis (2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-16.
10. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agent bis (2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8.
11. Jensen PB, Jensen PS, Demant EJ et al. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 1991; 51: 5093-9.
12. Rion JF, Fosse P, Nguyen CH et al. Intoplicine (RP 60475) and its derivatives, a new class of antitumour agents inhibiting both topoisomerase I and II activities. Cancer Res 1993; 53: 5987-93.
13. Perrin D, van Hille B, Barret JM et al. F11782, a novel non-intercalating dual inhibitor of topoisomerases I and II with an original mechanism of action. Biochem Pharmacol 2000; 59: 807-19.
14. Drake FH, Hofmann GA, Mong SM et al. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 1989; 49: 2578-83.
15. Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase II by blocking DNA cleavage. J Biol Chem 1998; 273: 17 643-50.
16. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781-5.
17. Morris SK, Baird CL, Linsley JE. Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193. J Biol Chem 2000; 275: 2613-8.
18. Takahashi C, Numata A, Ito Y et al. Leptosins, antitumor metabolites of a fungus isolated from a marine alga. J Chem Soc Perkin Trans 1994; 1: 1859-64.
19. Umerura K, Mizushima T, Katayama H, Kiryu Y, Yamori T, Andoh T. Inhibition of DNA topoisomerase II and/or I by pyrazolo [1, 5-a] indole derivatives and their growth inhibitory activities. Mol Pharmacol 2002; 62: 873-80.
20. Ishii K, Hasegawa T, Fujisawa K, Andoh T. Rapid purification and characterization of DNA topoisomerase I from cultured mouse mammary carcinoma FM3A cells. J Biol Chem 1983; 258: 12 728-32.
21. Yanase K, Sugimoto Y, Andoh T, Tsuruo T. Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance. Int J Cancer 1999; 81: 134-40.
22. Simpson AM, Simpson L. Isolation and characterization of kinetoplast DNA networks and minicircles from Crithidia fasciculata. J Protozool 1974; 21: 774-81.
23. Shapiro TA, Klein VA, Englund PT. Isolation of kinetoplast DNA. Methods Mol Biol 1999; 94: 61-7.
24. Sato S, Fukuda Y, Nakagawa R, Tsuji T, Umemura K, Andoh T. Inhibition of DNA topoisomerases by nidulalin A derivatives. Biol Pharm Bull 2000; 23: 511-2.
25. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14 873-8.
26. Andoh T, Ishii K, Suzuki Y et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 1987; 84: 5565-9.
27. Alley MC, Scudiero DA, Monks A et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48: 589-601.
28. Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein, BAG-1, binds to and activate the kinase Raf-1. Proc Natl Acad Sci USA 1996; 93: 7063-8.
29. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-6.
30. Kaufmann SH, Svingen PA. Immunoblot analysis and band depletion assays. Methods Mol Biol 1999; 94: 253-68.
31. Yamori T, Matsunaga A, Sato S et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999; 59: 4042-9.
32. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 1972; 32: 2643-50.
33. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33: 2834-6.
34. Liu LF. Biochemistry of camptothecin. In: Milan P, Pinado H, eds. Camptothecins: New Antitumor Agents. Boca Raton: CRC Press, 1995; 9-19.
35. Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267: 2003-6.
36. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88: 435-7.
37. Nakashio A, Fujita N, Rokudai S, Sato S, Tsuruo T. Prevention of phosphatidylinositol 3-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 2000; 60: 5303-9.
38. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279: 1504-13.
39. Zhang HS, Cao EH, Qin JF. Homocysteine induces cell cycle G1 arrest in endothelial cells through the PI3K/Akt/FOXO signaling pathway. Pharmacology 2005; 74: 57-64.
40. Yusuf I, Zhu X, Kharas MG, Chen J, Fruman DA. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood 2004; 104: 784-7.
41. Drolet M, Wu HY, Liu LF. Roles of DNA topoisomerases in transcription. In: Liu LF, ed. DNA Topoisomerases: Biochemistry and Molecular Biology. Massachusetts: Academic Press, 1994; 135-46.
42. Fujiwara H, Yamakuni T, Ueno M et al. IC101 induces apoptosis by Akt dephosphorylation via an inhibition of heat shock protein 90-ATP binding activity accompanied by preventing the interaction with Akt in L1210 cells. J Pharmacol Exp Ther 2004; 310: 1288-95.
43. Kulp SK, Yang YT, Hung CC et al. 3-Phosphoinoditide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004; 64: 1444-51.
44. Lee TK, Man K, Ho JW et al. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004; 25: 2397-405.
45. Suzuki T, Kobayashi M, Isatsu K et al. Mechanisms involved in apoptosis of human macrophages induced by lipopolysaccharide from actinobacillus actinomycetemcomitans in the presence of cycloheximide. Infect Immune 2004; 72: 1856-65.
46. Rokudai S, Fujita N, Hashimoto Y, Tsuruo T. Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis. J Cell Physiol 2000; 182: 290-6.
47. Morham SG, Kluckman KD, Voulomanos N, Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol 1996; 16: 6804-9.